Global pharma major Lupin Limited has entered an exclusive licensing agreement with Valorum Biologics, marking another strategic step in strengthening its US biosimilars footprint.
The collaboration focuses on Armlupeg (pegfilgrastim-unne), Lupin’s biosimilar designed to support patients undergoing chemotherapy by reducing neutropenia duration.
Under the agreement, each company brings its core strengths to the table:
This structure ensures operational efficiency while accelerating market access for patients who depend on pegfilgrastim during chemotherapy.
Pegfilgrastim plays a critical role in oncology supportive care. It reduces the duration of chemotherapy-induced neutropenia and lowers infection-related risks.
Both companies emphasize the shared goal of improving access and affordability:
Spiro Gavaris, President of US Generics at Lupin, highlighted the company’s vision:
“This partnership reflects our mission to make high-quality biosimilars more accessible and improve patient outcomes.”
Par S. Hyare, CEO of Valorum, added:
“Our commercial experience positions us to capture strong market share while offering providers and patients another important treatment option.”
The deal reinforces several broader industry trends:
Lupin, already active in the global biosimilar space, continues to leverage strategic alliances to scale faster in mature markets such as the US.
As Valorum prepares for the US launch of Armlupeg, the focus now shifts to:
With both companies aligned on affordability and quality, the partnership sets the stage for stronger biosimilar penetration in a critical therapeutic category.